SB Sleep Breathe Well Sleep & Pulmonary Education
Home › Sleep › Sleep Apnea / CPAP Alternatives

Alternatives to CPAP for Sleep Apnea

When CPAP is not tolerated or is insufficient, other evidence-based options exist. This page covers surgical procedures, hypoglossal nerve stimulation (HGNS), oral appliance therapy, and weight management — including who qualifies, what the evidence shows, and what to expect.

Surgical Options

Airway surgery for OSA

Surgery aims to enlarge or stabilize the upper airway at one or more levels of obstruction. It is generally considered when positive airway pressure (PAP) therapy has been trialed and is not tolerated or effective, or when anatomic factors make surgery a reasonable option.[1,2]

Uvulopalatopharyngoplasty (UPPP)
  • What it is: The most commonly performed OSA surgery. Tissue is removed or repositioned from the soft palate, uvula, and pharyngeal walls to widen the retropalatal airway.
  • Success rates: Meta-analyses report approximately 40–50% surgical success (defined as ≥50% AHI reduction to <20 events/hour). Success is higher in patients with isolated retropalatal obstruction and lower BMI.[2]
  • Recurrence: OSA can recur over time as tissue may scar, sag, or as weight is regained. Long-term studies suggest some loss of benefit beyond 2–3 years.
  • Complications: Throat pain (1–2 weeks), difficulty swallowing, velopharyngeal insufficiency (nasal regurgitation of liquids), voice changes, dryness, and rarely bleeding. General anesthesia carries standard risks.
  • What to expect: Recovery takes 2–3 weeks with significant throat pain. A soft diet is needed initially. A follow-up sleep study is recommended 3–6 months after surgery to assess residual OSA.
Tonsillectomy and adenoidectomy
  • What it is: Removal of enlarged tonsils and/or adenoids. First-line surgical treatment in children with OSA. In adults, considered when tonsillar hypertrophy (grade 3–4) contributes to airway narrowing.
  • Success rates: In children, cure rates exceed 70–80%. In adults with significant tonsil enlargement, success rates can be 60–80%.[1]
  • Recurrence: In children, OSA can recur with weight gain during adolescence. In adults, recurrence depends on other contributing sites of obstruction.
  • Complications: Pain for 7–14 days, risk of post-operative bleeding (2–4%), rare infection, temporary voice changes, and dehydration from poor oral intake.
  • What to expect: 1–2 weeks recovery. Follow-up sleep study recommended 6–8 weeks post-surgery, especially if moderate-to-severe OSA was present pre-operatively.
Maxillomandibular advancement (MMA)
  • What it is: Both the upper jaw (maxilla) and lower jaw (mandible) are surgically moved forward, enlarging the entire retrolingual and retropalatal airway. Considered the most effective single surgical procedure for OSA.[2]
  • Success rates: Surgical success rates of 75–100% in well-selected patients. Mean AHI reduction is often greater than 80%. Considered when other interventions have failed or when craniofacial anatomy is a primary contributor.[2]
  • Recurrence: Long-term durability is generally better than soft tissue procedures because the skeletal framework is permanently altered. Some studies report sustained benefit at 5+ years.
  • Complications: Numbness of the lower lip or chin (often temporary, sometimes permanent), jaw stiffness, malocclusion requiring orthodontic adjustment, infection, non-union of bone segments, facial appearance changes, and general anesthesia risks.
  • What to expect: This is a major surgery typically requiring 1–2 nights in the hospital. Recovery involves a modified diet for 4–6 weeks, potential jaw wiring or banding, and 6–12 weeks before full activity. Pre-operative orthodontics may be needed. A follow-up sleep study is performed 3–6 months post-surgery.
Genioglossus advancement
  • What it is: A section of the chin bone where the genioglossus (main tongue) muscle attaches is cut and pulled forward, preventing the tongue from falling backward during sleep.
  • Success rates: Often performed alongside UPPP as part of multilevel surgery. Isolated success data are limited, but it contributes to overall AHI reduction when combined with palatal surgery.
  • Complications: Lower tooth numbness, chin contour changes, infection, tooth root injury, and hematoma formation.
  • What to expect: Generally performed as part of a combined procedure. Recovery overlaps with the palatal surgery recovery timeline (2–3 weeks).
Hyoid suspension
  • What it is: The hyoid bone is repositioned and fixed forward or to the mandible, pulling the tongue base and epiglottis anteriorly. Usually combined with other procedures.
  • Success rates: Limited as a standalone procedure. Most evidence supports it as an adjunct in multilevel surgery.
  • Complications: Difficulty swallowing, neck stiffness, and rare infection.
Tongue base reduction and epiglottoplasty
  • What it is: Various techniques (radiofrequency ablation, coblation, robotic-assisted surgery) reduce tongue base tissue or reshape the epiglottis to improve the hypopharyngeal airway.
  • Success rates: Variable. Transoral robotic surgery (TORS) lingual tonsillectomy and tongue base reduction have shown promise in selected patients, particularly those with lingual tonsillar hypertrophy identified on drug-induced sleep endoscopy (DISE).[2]
  • Complications: Throat pain, bleeding, taste disturbance, tongue swelling (airway monitoring needed post-operatively), and difficulty swallowing.
  • What to expect: May require overnight observation for airway monitoring. Recovery is 1–2 weeks for most techniques.

General considerations for OSA surgery

  • Pre-operative evaluation: Drug-induced sleep endoscopy (DISE) is often performed before surgery to identify the specific site(s) and pattern of airway collapse, which guides surgical planning.
  • A recent sleep study (within 1–2 years) is needed to confirm current OSA severity.
  • Post-operative sleep testing is recommended after all surgical interventions to document residual OSA severity and determine if further treatment is needed.
  • Combination (multilevel) surgery targeting more than one anatomic level generally has higher success rates than single-site procedures.
  • Weight gain after surgery can lead to OSA recurrence, regardless of the procedure performed.
  • Surgery does not guarantee a cure. Some patients still require CPAP or other therapy after surgery, potentially at lower and more tolerable pressures.
Implant Therapy

Hypoglossal nerve stimulation (HGNS)

Hypoglossal nerve stimulation is an implantable device that stimulates the hypoglossal nerve to push the tongue forward during sleep, preventing airway collapse. The Inspire system is the most widely studied and FDA-approved device.[3,4]

Who qualifies?

  • Adults with moderate-to-severe OSA (AHI 15–65 events/hour on the original STAR trial criteria; some expanded criteria now used)
  • Unable to tolerate or benefit adequately from CPAP
  • BMI ≤ 32 (originally per STAR trial; some centers now consider patients up to BMI 35 based on expanded data)[3,5]
  • Absence of complete concentric palatal collapse on drug-induced sleep endoscopy (DISE) — this specific collapse pattern predicts poor response to HGNS
  • No significant central or mixed sleep apnea component
  • No untreated significant medical conditions that would increase surgical risk

Evidence supporting HGNS

  • STAR trial: The pivotal prospective multicenter trial enrolled 126 patients. Mean AHI decreased from 32 to 15.3 events/hour at 12 months. Five-year follow-up (n = 97) showed sustained benefit with mean AHI of 12.4 events/hour.[3]
  • ADHERE registry: The largest real-world registry with 5,000 patients across 61 US and European centers. Post-titration data showed a 62% median decrease in AHI. Mean nightly usage was 6.4 hours (higher than typical CPAP adherence).[4]
  • Adherence advantage: Real-world comparison data suggest HGNS adherence at 30 days is approximately 93% versus 56% for CPAP. Superior adherence may translate to better real-world disease control even when AHI reduction is less dramatic than optimal CPAP.[4]
  • Daytime sleepiness: Significant improvement in Epworth Sleepiness Scale (ESS) scores, typically decreasing to normal range (≤10) after therapy optimization.

Pre-operative requirements

  • Sleep study: A recent polysomnogram (within 2 years) confirming moderate-to-severe OSA and no predominant central apnea
  • Drug-induced sleep endoscopy (DISE): Required before implantation to rule out complete concentric palatal collapse. This is an outpatient procedure performed under sedation where the upper airway is visualized during simulated sleep.
  • Medical clearance: Standard pre-operative evaluation; patients with pacemakers or certain implanted devices may need additional workup
  • MRI compatibility: Newer Inspire devices are MRI-conditional under specific conditions. Discuss MRI needs with the implanting surgeon before the procedure.

What to expect: the procedure

  • Surgery: Outpatient or one-night hospital stay. Three small incisions (below chin, upper chest for pulse generator, and between ribs for sensing lead). The procedure takes approximately 2–3 hours under general anesthesia.
  • Recovery: Most patients return to non-strenuous activity within 1–2 weeks. Sutures are typically absorbable. Activity restrictions (no heavy lifting) for about 4 weeks.
  • Activation: The device is not turned on immediately. Activation typically occurs approximately 4–6 weeks after surgery to allow tissue healing around the leads. An in-office visit is required to program and activate the device.
  • Initial settings: The device is started at a low stimulation voltage and gradually increased over several weeks to find the therapeutic range.

After surgery: the full timeline

  • Weeks 1–4 (healing period): The device remains off while tissue heals around the leads. Patients recover from surgery, with most returning to normal activity within 1–2 weeks. Sutures are typically absorbable. Activity restrictions (no heavy lifting) for about 4 weeks.
  • Week 3–6 (activation visit): An in-office visit where the device is turned on for the first time and initial settings are programmed. The clinician tests tongue protrusion response and sets a starting voltage, typically low (around 0.6–0.8 V). The patient receives their handheld remote control and learns to operate the device.
  • Weeks 6–16 (home self-titration): The patient gradually increases the stimulation voltage at home, typically advancing one step (0.1 V) every few days to once per week, based on comfort and tolerance. The goal is to find the therapeutic threshold — the voltage that opens the airway without causing discomfort or awakening. Follow-up clinic visits are typically scheduled every 2–4 weeks during this period to review progress and adjust settings.[3,4]
  • Home sleep testing during titration: Some centers now use longitudinal home sleep apnea testing (HSAT) during the titration period to track AHI at each voltage level, allowing objective monitoring between clinic visits. This newer approach can shorten the titration period — studies show that frequent HSAT monitoring can reduce the traditional 90–120 day titration to approximately 60 days while maintaining outcomes.[4]
  • Remote monitoring: Inspire devices track nightly usage data (hours of use per night) that can be downloaded at clinic visits. The newer Inspire V system (FDA approved August 2024) includes Bluetooth connectivity for enhanced remote monitoring capabilities, and eliminates the need for a separate respiratory sensing lead.[4]

The in-lab titration study

  • When: An overnight in-lab polysomnogram (PSG) is scheduled approximately 2–4 months after activation, once the patient has reached a comfortable and presumably therapeutic voltage through home self-titration.
  • Purpose: Similar to a CPAP titration, the sleep physician and technologist systematically evaluate different voltage settings, electrode configurations, timing parameters, and body positions during monitored sleep to find the optimal settings that produce the lowest AHI.
  • How it's done: The patient sleeps with the device on while the technologist adjusts settings at the bedside. The AHI is measured at each voltage level (e.g., 0.8 V, 1.0 V, 1.2 V, etc.) to find the sweet spot between efficacy and comfort. The therapy cycle timing (stimulation on/off pattern synchronized with breathing) is also optimized.
  • Green vs. Yellow pathway: After titration, patients are classified based on outcomes. "Green pathway" patients achieve AHI <15, use the device >4 hours/night, and report subjective improvement. "Yellow pathway" patients may need further adjustments, alternative electrode configurations, or supplemental therapy.
  • When to expect results: Most patients notice improvements in snoring and daytime sleepiness within weeks of activation. Full optimization typically takes 3–6 months, though some patients require up to 12 months of titration adjustments. The 5,000-patient ADHERE registry showed 90% of physicians reported improvement in their patients after optimization.[4]
  • Confirming effectiveness: A post-titration sleep study documents the final AHI. Success is defined as AHI reduction ≥50% to <20 events/hour. In the ADHERE registry, post-titration studies showed a 62% median decrease in AHI.

Complications and issues

  • Tongue discomfort or abrasion: The most common side effect. The tongue protrusion sensation can take time to adjust to. Some patients experience tongue soreness, especially early on.
  • Device discomfort: Mild chest wall discomfort at the generator site, typically temporary.
  • Lead migration or malfunction: Uncommon but may require revision surgery.
  • Infection: Rare post-operative infection at the incision sites. If the device becomes infected, explantation may be necessary.
  • Tongue weakness: Temporary or persistent tongue weakness is rare but reported. No cases of permanent hypoglossal nerve palsy in the STAR trial.
  • Inadequate response: Some patients do not achieve adequate AHI reduction despite optimization. Alternative or adjunctive therapy may be needed.
  • Weight gain: As with all OSA therapies, weight gain can worsen OSA beyond the device's ability to compensate.
  • Not a cure: HGNS is a therapy, not a cure. If the device is turned off, OSA returns.

Alternatives to HGNS

Patients who do not qualify for or prefer alternatives to HGNS may consider oral appliance therapy, upper airway surgery, weight management, positional therapy, or combination approaches. Each option is discussed elsewhere on this page.

Dental Device

Oral appliance therapy (OAT)

Oral appliances (mandibular advancement devices) are custom-fitted dental devices that hold the lower jaw and tongue forward during sleep, enlarging the upper airway.[6]

Who qualifies?

  • Patients with mild-to-moderate OSA (AHI 5–30) as a primary therapy[6]
  • Patients with severe OSA who cannot tolerate or refuse CPAP
  • Patients who prefer an alternative to CPAP after informed shared decision-making
  • Adequate dentition is required — patients need enough healthy teeth to anchor the device (usually ≥8–10 teeth per arch)
  • Patients with active TMJ disorder, severe periodontal disease, or insufficient teeth may not be candidates
  • Oral appliances must be custom-fabricated by a qualified dentist trained in dental sleep medicine — over-the-counter "boil-and-bite" devices are not recommended[6]

OAT vs. CPAP: evidence

  • AHI reduction: CPAP is more effective than OAT at lowering AHI in most comparative studies. CPAP typically achieves near-complete normalization of AHI when used consistently.[6,7]
  • Real-world equivalence: However, because OAT adherence tends to be higher than CPAP adherence, the overall "disease alleviation" (effectiveness × hours of use) may be similar in some patient populations, particularly in mild-to-moderate OSA.[7]
  • Blood pressure: Some studies suggest similar reductions in blood pressure with OAT and CPAP, likely because the net therapeutic effect depends on actual hours of use.
  • Quality of life: Patient satisfaction and quality of life ratings are often similar or higher with OAT compared to CPAP.
  • Severe OSA: In severe OSA, CPAP is generally preferred because the magnitude of AHI reduction with OAT alone may be insufficient. However, OAT can be considered if CPAP is truly not tolerated.

The need for repeat sleep testing

  • After fitting: A follow-up sleep study with the oral appliance in place is essential to confirm it is adequately treating the OSA. The device is gradually titrated (advanced) over weeks, and the sleep study is performed once the optimal jaw position is reached.
  • Why it matters: Unlike CPAP, which shows real-time efficacy data, oral appliances do not provide nightly feedback on AHI. Without a sleep study, there is no way to know if the device is effectively treating the condition.
  • Ongoing monitoring: Repeat sleep testing may be needed if symptoms return, weight changes significantly, or jaw position needs readjustment.
  • If OAT is insufficient: Combination therapy (OAT + positional therapy, or OAT at a reduced CPAP pressure) may be considered.

Complications and what to watch for

  • Jaw pain or TMJ discomfort: Common early on, usually improves with time. If persistent, the device may need adjustment or an alternative may be needed.
  • Bite changes: Long-term use can gradually shift tooth alignment and bite (dental occlusion). Regular dental follow-up is essential. Morning jaw exercises can reduce this risk.
  • Excessive salivation or dry mouth: Depending on design, some patients experience one or the other during the adjustment period.
  • Tooth loosening or gum irritation: Especially in patients with underlying periodontal disease.
  • Device breakage: Custom devices are durable but not indestructible; typical lifespan is 3–5 years.
  • Incomplete treatment: The most important risk. Without follow-up sleep testing, a patient may believe the device is working based on subjective improvement in snoring while significant OSA persists.
Weight Management

Weight loss and obstructive sleep apnea

Excess weight is the strongest modifiable risk factor for OSA. Fat deposition around the upper airway, tongue, and neck narrows the airway and promotes collapse during sleep. Weight loss can significantly improve or, in some cases, resolve OSA.[8,9]

Does weight loss resolve or improve OSA?

  • Improvement is consistent: Nearly all studies show that weight loss reduces AHI and improves OSA severity. A 10–15% reduction in body weight is associated with approximately 30–50% reduction in AHI.[8]
  • Complete resolution is possible but not guaranteed: Some patients with mild-to-moderate OSA and obesity do achieve AHI normalization with sufficient weight loss. However, many patients still have residual OSA even after significant weight loss, especially if baseline OSA was severe or if structural craniofacial factors contribute.[9]
  • The Sleep AHEAD study (a sub-study of the Look AHEAD trial) showed that intensive lifestyle intervention producing ~10 kg weight loss at 1 year resulted in 3× higher odds of OSA remission compared to standard education. However, only about 35% of participants with OSA at baseline achieved remission.[8]
  • Weight regain leads to OSA recurrence: If weight is regained, OSA typically worsens again. Sustained weight management is essential.
  • Post-weight-loss sleep testing: A follow-up sleep study is recommended after significant weight loss to reassess OSA severity and determine whether CPAP settings need adjustment or can be discontinued.

Weight loss medications

  • GLP-1 receptor agonists (semaglutide [Wegovy/Ozempic], tirzepatide [Zepbound/Mounjaro]) have shown substantial weight loss in clinical trials (15–22% body weight loss). These medications are increasingly used in patients with OSA and obesity, but must be combined with lifestyle changes.[9]
  • SURMOUNT-OSA trial: Tirzepatide produced a 55% reduction in AHI from baseline (vs. 5% for placebo) and 18% body weight reduction over 52 weeks. Up to 50% of participants no longer met criteria for moderate-to-severe OSA after one year of treatment. These results were published in the New England Journal of Medicine in 2024.[9]
  • FDA approval: Tirzepatide (Zepbound) received FDA approval in December 2024 as the first and only prescription medication for moderate-to-severe OSA in adults with obesity. The FDA label requires concurrent use with a reduced-calorie diet and increased physical activity.
  • Lifestyle modification is essential: Weight loss medications are not a substitute for healthy habits. They are most effective and durable when combined with dietary changes (balanced, reduced-calorie eating patterns), regular physical activity (150+ minutes/week of moderate exercise), behavioral counseling, and structured follow-up. Without lifestyle changes, medication alone produces smaller and less sustainable results.
  • Limitations: These medications require ongoing use to maintain weight loss — if discontinued, weight typically rebounds and OSA worsens. Cost and insurance coverage remain significant barriers. Long-term safety data beyond 2–3 years are still accumulating. GI side effects (nausea, vomiting, diarrhea) are common, especially during dose escalation.
  • Not a replacement for PAP: While weight loss medications can improve OSA, they should not be considered a replacement for PAP therapy in patients with severe OSA until a follow-up sleep study confirms adequate improvement.

Bariatric (weight loss) surgery

  • Magnitude of weight loss: Bariatric surgery produces the largest sustained weight reductions (20–35% of total body weight). The most common procedures are sleeve gastrectomy and Roux-en-Y gastric bypass.
  • Effect on OSA: Meta-analyses show that bariatric surgery significantly reduces AHI in most patients, and a substantial proportion achieve OSA resolution (AHI <5). However, residual OSA remains common — approximately 40–50% of patients still have at least mild OSA after bariatric surgery.[9]
  • Post-surgical sleep testing: A follow-up sleep study is strongly recommended after bariatric surgery to reassess OSA and CPAP needs, even if symptoms have improved.

Medications vs. bariatric surgery

  • Weight loss magnitude: Bariatric surgery generally produces greater weight loss (25–35%) than current medications (15–22%), though newer dual and triple agonist medications are narrowing this gap.
  • Durability: Bariatric surgery effects tend to be more durable (10+ year data), whereas medication benefits require continued use.
  • Risks: Surgery carries procedural risks (bleeding, leak, infection, nutritional deficiencies) but is a one-time intervention. Medications have GI side effects (nausea, vomiting) and theoretical concerns about pancreatitis and thyroid tumors, though serious events remain uncommon.
  • Bottom line: Both approaches can meaningfully improve OSA, but neither guarantees OSA resolution. Weight management is best viewed as a complementary therapy alongside other OSA treatments, not as a standalone substitute for PAP in most patients with moderate-to-severe disease.
  • Sustained lifestyle changes are critical: Regardless of whether medication or surgery is used, long-term success depends on sustained dietary modification (whole foods, balanced macronutrients, portion control), regular exercise, behavioral support, and ongoing clinical follow-up. Without these, weight regain is common and OSA recurs.

Related topics

Trusted resources

References

  1. Epstein LJ, Kristo D, Strollo PJ Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5(3):263-276. doi:10.5664/jcsm.27497
  2. Kent D, Stanley J, Aurora RN, et al. Referral of adults with obstructive sleep apnea for surgical consultation: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(12):2499-2505. doi:10.5664/jcsm.9592
  3. Strollo PJ Jr, Soose RJ, Maurer JT, et al. Upper-airway stimulation for obstructive sleep apnea. N Engl J Med. 2014;370(2):139-149. doi:10.1056/NEJMoa1308659
  4. Thaler E, Schwab R, Maurer J, et al. Results of the ADHERE upper airway stimulation registry and predictors of therapy efficacy. Laryngoscope. 2020;130(5):1333-1338. doi:10.1002/lary.28286
  5. Woodson BT, Strohl KP, Soose RJ, et al. Upper airway stimulation for obstructive sleep apnea: 5-year outcomes. Otolaryngol Head Neck Surg. 2018;159(1):194-202. doi:10.1177/0194599818762383
  6. Ramar K, Dort LC, Katz SG, et al. Clinical practice guideline for the treatment of obstructive sleep apnea and snoring with oral appliance therapy: an update for 2015. J Clin Sleep Med. 2015;11(7):773-827. doi:10.5664/jcsm.4858
  7. Schwartz M, Acosta L, Hung YL, Padilla M, Enciso R. Effects of CPAP and mandibular advancement device treatment in obstructive sleep apnea patients: a systematic review and meta-analysis. Sleep Breath. 2018;22(3):555-568. doi:10.1007/s11325-017-1590-6
  8. Foster GD, Borradaile KE, Sanders MH, et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med. 2009;169(17):1619-1626. doi:10.1001/archinternmed.2009.266
  9. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391(13):1193-1205. doi:10.1056/NEJMoa2404881
This information is for general education only. CPAP alternatives require evaluation by a sleep specialist and, for surgical procedures, a surgeon experienced in sleep surgery. Not all options are appropriate for every patient. Always discuss treatment decisions with your medical team.